Participated · Equity · Apr 2026

Founded in 2020 and based in Épinay-sous-Sénart (Essonne), Cosmyx develops and manufactures 3D printers and micro-usines 3D for industrial-scale additive manufacturing. The company positions itself to help industrial clients transition from prototyping to mass production and has been active in the defense sector. Cosmyx currently employs around fifteen people and plans to recruit additional staff following its recent fundraising. With the new capital, it aims to expand its commercial pipeline and pursue opportunities in medical, aeronautics, and nuclear markets. Financial details beyond the recent €1.3 million raise were not disclosed in the article.

Participated · Equity · Apr 2026

Founded in 2023 in Pessac near Bordeaux, Luchrome develops Lusight™, an electrochromic, bistable e‑paper display printed by screen‑printing onto paper without solvents or rare metals. The technology, originating from academic research at the Institut de Chimie de la Matière Condensée de Bordeaux, is produced locally in Pessac and is claimed to consume ten times less energy, cost one‑third of conventional displays to produce and have up to sixty times lower environmental impact. Luchrome targets IoT applications including cold‑chain monitoring for high‑value pharmaceuticals, logistics labels, smart packaging and single‑use medical diagnostics, with a near‑term commercial goal of 25 million units and Lusight™ available for pre‑order in 2026. The company has formed a partnership with BeFC to pair its paper display with a compostable paper‑based battery and has been scaling manufacturing capacity with funds raised to acquire a second industrial tool.

Participated · Equity · Nov 2025

Fluiidd, a deep-tech spin-off from the French Commissariat à l’énergie atomique et aux énergies alternatives (CEA) and based in La Ciotat, builds and markets an intelligent scanner that uncovers and anticipates otherwise invisible defects in pipes. The product combines proprietary sensors with predictive artificial-intelligence algorithms to flag upcoming failures before they occur. Following its first fund-raise, the company plans to scale its marketing and sales teams to speed up commercial rollout both across France and internationally. Funds will also support continued R&D aimed at enriching the scanner’s predictive capabilities and industrialising the production of its smart sensors. Although no revenue or user figures were disclosed, management positions the technology as a preventive-maintenance tool for industrial clients, addressing costly unplanned shutdowns. The company’s current focus is on market penetration and product industrialisation, backed by new capital from regional and angel investors.

Participated · Series A · Oct 2025

Founded in 2019 and headquartered in Roscoff, SeaBeLife engineers dual-acting small molecules designed to block both necroptosis and ferroptosis, two regulated cell-death pathways that drive tissue damage in several acute and chronic diseases. Its lead candidates are SBL03 for dry age-related macular degeneration (with recent positive in-vivo data in geographic atrophy) and SBL01 for severe acute hepatitis, both addressing large unmet medical needs. The company plans to begin first-in-human clinical trials in 2026. SeaBeLife’s pipeline is positioned as a potentially transformative, first-in-class approach to organ protection, differentiating it from single-pathway competitors. To date, the firm has attracted €9 million in total funding through a mix of equity and public grants, including support from Bpifrance, SATT Ouest Valorisation, Biotech Santé Bretagne, and the Région Bretagne. The new capital strengthens its runway as the team prepares for a larger Series A round to finance clinical studies and expand development of its multi-target platform.

Participated · Seed · May 2024

Hephaistos-Pharma is a preclinical biotech developing ONCO-Boost, a first‑in‑class intravenous immunostimulant that targets the innate immune response to treat cancers non‑responding to current regimens. The company is focused on enabling treatment of metastatic and hard‑to‑treat indications. Led by CEO Frederic Caroff, Hephaistos uses a technology designed for intravenous administration to reach systemic disease. It plans to use the new funding to expand operations and accelerate R&D. Hephaistos is part of the SyStInn consortium, which received additional grant funding to support clinical evaluation of ONCO-Boost. The company has operations in Lyon, France and a subsidiary in Liège, Belgium. HEPHAISTOS-Pharma develops next-generation immunotherapies for cancer, with a lead candidate called ONCO-Boost targeting solid tumors, notably sarcoma. The company plans to use new funding to finance GMP transfer and to advance ONCO-Boost toward clinical development. Proceeds will enable industrialization of its manufacturing process and preparation for clinical phases. HEPHAISTOS also intends to open a new subsidiary in Liège, Wallonia to leverage local facilities and expertise, explore additional applications, and strengthen its pipeline. Frederic Caroff is CEO and co-founder.